Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Henagliflozin, Retagliptin and Metformin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
This is a single extended-release tablet that combines three type 2 diabetes medicines: henagliflozin, retagliptin and metformin. It was developed in China by Jiangsu Hengrui Pharmaceuticals, its Chinese name is 恒格列净瑞格列汀二甲双胍缓释片, its brand name is 瑞乐唐®, and its research code was HR20031. Hengrui describes it as China's first home-grown three-in-one oral diabetes tablet. The idea is simple: fewer tablets to remember, which can make a long-term plan easier to follow.
China's National Medical Products Administration (NMPA) approved it in October 2025, as a prescription medicine (approval numbers 国药准字 H20250063 for strength I and H20250064 for strength II), for:
It is a prescription endocrinology medicine and should be started and monitored by a diabetologist or endocrinologist.
Each of the three ingredients lowers blood sugar in a different way:
The key phase 3 trial, published in Diabetes, Obesity and Metabolism in 2024, included about 780 adults in China whose diabetes was not controlled on metformin. Everyone stayed on metformin and added retagliptin 100 mg, henagliflozin 5 mg or 10 mg, or retagliptin together with henagliflozin, once daily for 24 weeks.
This trial used the three medicines as separate tablets; the combined tablet puts the same ingredients into one tablet.
According to the Chinese prescribing information, it is usually taken once a day in the morning with a meal. The dose is chosen from the patient's current treatment, how well it is working and how well it is tolerated. Two strengths are approved (henagliflozin/retagliptin/metformin):
The tablets are extended-release, so they should be swallowed as directed on the leaflet. Your doctor decides which strength suits you.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
In the phase 3 study behind the approval, genital and urinary infections, a known concern with SGLT2 inhibitors, were reported in 1.9% of people, and no severe low blood sugar was reported. Side effects seen in at least 2% of people were weight loss (10.9%), raised lipase (7.1%), ketones in the urine (4.5%) and sugar in the urine (3.8%). Because the metformin is in extended-release form, stomach upset was uncommon: nausea 6.3%, vomiting 2.1% and diarrhoea 2.1%.
Because the tablet contains metformin, an SGLT2 inhibitor and a DPP-4 inhibitor, the standard cautions for each of these medicine types apply, and your doctor will go through them with you:
In the trial: side effects with the three medicines together were reported at rates similar to the single add-ons, and no episodes of severe low blood sugar were seen. The risk of low blood sugar can rise if it is combined with insulin or sulfonylureas. Safety in pregnancy, breastfeeding and children has not been established, so speak to your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. This combination is approved only in China. Neither henagliflozin nor retagliptin appears in CDSCO's lists of new drugs approved in India, the tablet is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it already contains metformin, your doctor will review your existing diabetes tablets before you switch.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are stored as directed on the pack and travel in their sealed original packs under temperature-controlled shipping. We confirm the strength, (I) or (II), on the prescription before ordering, so the right pack is imported. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Diabetes clinics in Delhi see patients from across North India, and our New Delhi dispatch point keeps delivery quick.
Diabetologists in Mumbai can request the combined tablet for a named patient, with the strength confirmed before import.
Patients in Bangalore can have the tablets delivered home or to their clinic once the documents are checked.
The treating doctor can share the prescription, HbA1c and kidney report with us to begin the import.
Endocrinologists in Hyderabad can arrange supply for patients who want to cut down the number of daily diabetes tablets.
For Kolkata and the eastern states, deliveries are planned so the next pack arrives before the current one runs out.
Patients in Pune can use the same documented import route, with updates at each stage.
Doctors across Gujarat can request supply for individual patients through the Named Patient Program.
Patients in Jaipur and across Rajasthan can receive the tablets at home or at the treating clinic.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or doctor.
We deliver to patients and diabetes clinics across Uttar Pradesh.
Patients in Kochi and across Kerala can receive the medicine through the same legal route.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
